Kerri Fitzgerald

Cancer Nursing Today nonprod

A study published in the American Journal of Blood Research observed a link between serum ferritin level and fibrosis in older patients with myelofibrosis (MF).Researchers retrospectively assessed 46 patients (median age, 66 years; 52.2% were male) with MF diagnosed between 2012 and 2020; patients were categorized as having primary MF (n=30; 28.3%), secondary MF (n=26; 56.5%), and myeloproliferative neoplasms with myelodysplastic syndromes (MDS/MPN; n=7; 15.2%).Median serum ferritin level was 132.5 ng/mL; 65.2% were normal, 21.8% were high but did not require treatment (between 300 ng/mL and 1,500 ng/mL), and 13% were high and required treatment (1,500 ng/mL and above). About one-third of patients (34.8%) had 10 or more erythrocyte transfusions in the last year. A little more than half of patients (n=26; 56.5%) did not receive transfusion and did not use ruxolitinib or chelation therapy.Researchers observed no relationship between serum ferritin and splenomegaly in any of the cases or subgroup analyses (P&gt;0.05). There was a statistically significant relationship between serum ferritin and marrow fibrosis among those aged 60 years and older (P=0.016), which accounted for 67.4% of cases in the study.&ldquo;Even though there was no statistically significant difference between serum ferritin level and splenomegaly in the general population in this study, a significant relationship has been demonstrated between fibrosis and ferritin in the group [aged] 60 years and older. In this respect, ferritin is very important in showing the relationship between fibrosis,&rdquo; the researchers concluded.

Link Between Serum Ferritin Level and Fibrosis in Older Patients with Myelofibrosis

Myelofibrosis

A study published in the American Journal of Blood Research observed a link between serum ferritin level and fibrosis in older patients with myelofibrosis (MF). Researchers retrospectively assessed 46 patients (median age, 66 years; 52.2% were male) with MF diagnosed between 2012 and 2020; patients were categorized as having primary MF (n=30; 28.3%), secondary MF [...]

About Us

Editorial Policy

Authors

Advertising

eNewsletters

Contact Us

Contribute

Calendar of Events

Career Center

Blood Cancers Today

GU Oncology Now

DocWire News

MashupMD

Urban Health Today

Breast Cancer

Colorectal Cancer

GI Cancer

GU Cancer

Gynecologic Cancer Awareness Month

Gyn-Onc

Blood Cancer Awareness Month

GVHD

Leukemia

Lymphoma

Myeloproliferative Neoplasms

Multiple Myeloma

Myelodysplastic Syndrome

Sickle Cell

Hem/Onc

Professional Development

Patient Voice

Lung Cancer

Skin Cancer

Other Tumor Types

News

Treatment

More

Conferences

Calendar

CARE Award

Best Practices

Expert Interviews

Subscribe